Corcept Therapeutics Incorporated (CORT) Earnings Call Analysis

NASDAQ · Healthcare · Biotechnology

23/25

Growth 5 Margin 5 Expansion 5 Platform 3 Financial 5

latest quarter score

Earnings Reports

23
Corset Therapeutics (CORT) Q2 2026: Lithioly Launch Adds $47.6M, Accelerating Oncology Expansion
July 30, 2026
12
CourseUp Therapeutics (CORT) Q1 2026: Oncology Launch Captures 200+ Prescribers, Guidance Raised on Endocrine Surge
May 01, 2026
10
CORT Q4 2025: 37% Tablet Volume Gain Reveals Cushing Franchise Demand Surge
February 25, 2026
12
CORT (CORT) Q3 2025: Hypercortisolism Tablets Surge 42.5% as Pipeline Expands Oncology Reach
November 05, 2025
13
CoreSep Therapeutics (CORT) Q2 2025: 49% Prescription Surge Outpaces Pharmacy Capacity, Setting Up Relacorlin Launch
July 31, 2025
13
CORT (CORT) Q1 2025: Relacorilant NDA and 100% Rx Surge Signal Expanding Hypercortisolism Market
July 06, 2025

Browse all companies